Core Viewpoint - Azitra, Inc. has entered into a securities purchase agreement to sell 3,339,300 shares of common stock at $0.2785 per share, aiming to raise approximately $930.0 thousand for working capital and general corporate purposes [1] Group 1: Offering Details - The offering is expected to close on February 5, 2025, subject to customary closing conditions [1] - Maxim Group LLC is acting as the sole placement agent for the offering [2] - The offering is made under an effective shelf registration statement previously filed with the SEC [3] Group 2: Company Overview - Azitra, Inc. is focused on developing innovative therapies for precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease [5] - ATR-12 is currently in a Phase 1b clinical trial for adult patients, while ATR-04 is being developed for EGFR inhibitor associated rash and has received Fast Track designation from the FDA [5] - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technology [5]

Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [2] - The company's lead product, ATR-12, is designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options [2] - ATR-12 is currently being evaluated in a Phase 1b clinical trial in adult patients with Netherton syndrome [2] - Azitra's second product, ATR-04, targets EGFR inhibitor associated rash, which affects approximately 150,000 people in the U.S. [2] - Azitra has received Fast Track designation from the FDA for ATR-04 [2] - The company utilizes a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by a microbial library of around 1,500 bacterial strains [2] Upcoming Events - Azitra will present at the BIO CEO & Investor Conference on February 10, 2025, at 3:45 p.m. ET in New York City [1] - The presentation will be led by Travis Whitfill, Chief Operating Officer, and will include one-on-one meetings with registered investors and potential partners [1]

Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [2] - The company's lead product, ATR-12, is designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options [2] - ATR-12 is currently being evaluated in a Phase 1b clinical trial in adult patients with Netherton syndrome [2] - Azitra's second product, ATR-04, targets EGFR inhibitor associated rash and has received Fast Track designation from the FDA [2] - Approximately 150,000 people in the U.S. are affected by EGFRi associated rash [2] - Azitra utilizes a proprietary platform of engineered proteins and a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning technology [2] Upcoming Events - Azitra will present at The Microcap Conference 2025 on January 29, 2025, at 11:00 a.m. ET [1] - The event will take place at Borgata Hotel Casino & Spa, Atlantic City, NJ [1] - CEO Francisco Salva will lead the presentation, and the management team will hold one-on-one meetings with registered investors and potential partners [1]

Core Viewpoint - Azitra, Inc. has announced a public offering of 4,857,780 shares of common stock at a price of $0.30 per share, aiming to raise approximately $1.5 million for working capital and corporate purposes [1]. Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease with no approved treatments [5]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome, while ATR-04 is being developed for EGFR inhibitor-associated rash, which affects around 150,000 people in the U.S. [5]. - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies [5]. Offering Details - The public offering is conducted under an effective shelf registration statement filed with the SEC, and the offering is expected to close on January 16, 2025 [3][1]. - Maxim Group LLC is acting as the sole placement agent for this offering [2].

Core Viewpoint - Azitra, Inc. has initiated a public offering of its common stock to raise funds for working capital and general corporate purposes [1][2]. Group 1: Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology [5]. - The company's lead product, ATR-12, targets Netherton syndrome, a rare skin disease with no approved treatments [5]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome [5]. - Azitra's second product, ATR-04, is being developed for EGFR inhibitor-associated rash and has received Fast Track designation from the FDA [5]. - Approximately 150,000 people in the U.S. are affected by EGFRi associated rash [5]. - Azitra utilizes a proprietary platform of engineered proteins and a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning technologies [5]. Group 2: Offering Details - The public offering is conducted under an effective shelf registration statement filed with the SEC [3]. - Maxim Group LLC is the sole placement agent for the offering [2]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1].

Core Viewpoint - Azitra, Inc. is set to present at the Biotech Showcase 2025, highlighting its innovative therapies for precision dermatology and engaging with investors and potential partners [1][2]. Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease [4]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients, while ATR-04 is being developed for EGFR inhibitor associated rash and has received Fast Track designation from the FDA [4]. - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies [4]. Event Details - The Biotech Showcase 2025 will take place from January 13-15, 2025, in San Francisco, with Azitra's COO Travis Whitfill presenting on January 13 at 3:00 p.m. PT [2][3]. - Azitra's management team will conduct one-on-one meetings with registered investors to discuss the company's business strategy, recent achievements, and future milestones [2].

Financial Performance - The company reported $0 service revenue for Q3 2024, down from $310,700 in Q3 2023[2] - Research and Development (R&D) expenses increased to $1.0 million in Q3 2024 from $0.5 million in Q3 2023, a 100% increase[3] - General and Administrative (G&A) expenses rose to $1.9 million in Q3 2024 compared to $1.8 million in Q3 2023[3] - The net loss for Q3 2024 was $1.0 million, an improvement from a net loss of $1.9 million in Q3 2023[3] - As of September 30, 2024, cash and cash equivalents stood at $7.3 million, up from $1.8 million at the end of 2023[4] Corporate Developments - Azitra completed a follow-on offering generating $10 million in gross proceeds[1] - Azitra strengthened its intellectual property portfolio with newly granted and allowed patents during the quarter[1] Clinical Trials and Regulatory Updates - The company anticipates initial safety data from the Phase 1b trial for Netherton syndrome patients in Q1 2025[2] - Azitra plans to dose the first patient with ATR-04 for EGFRi rash in a Phase 1/2 trial in Q1 2025[2] - The company has received Fast Track designation from the FDA for ATR-04, which targets EGFRi associated rash affecting approximately 150,000 patients in the U.S.[6]

Core Insights - Azitra, Inc. reported significant progress in Q3 2024, including the dosing of the first patient with ATR-12 for Netherton syndrome and the completion of a $10 million follow-on offering [2][3] - The company received FDA Fast Track designation for ATR-04, which is aimed at treating skin rash associated with EGFR inhibitors [2][3] - Azitra's financial results showed a net loss of $1.0 million for the quarter, a decrease from a loss of $1.9 million in the same period last year [3][9] Business Highlights - Completed a follow-on offering generating $10 million in gross proceeds [2] - Dosed the first patient with ATR-12 in the ongoing Netherton syndrome trial [2] - Submitted and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitors [2] - Presented positive preclinical data for ATR-04 at the EADV Congress [2] - Strengthened the intellectual property portfolio with newly granted patents [2] Pipeline and Anticipated Milestones - Q1 2025: Initial safety data from Netherton syndrome patients in Phase 1b trial [3] - Q1 2025: First patient dosed with ATR-04 for EGFRi rash in Phase 1/2 trial [3] - YE 2025: Topline data from the Phase 1b trial with ATR-12 expected [3] Financial Results - Service revenue for Q3 2024 was $0, down from $310,700 in Q3 2023 [3][9] - R&D expenses increased to $1.0 million from $0.5 million year-over-year [3][9] - G&A expenses slightly increased to $1.9 million from $1.8 million year-over-year [3][9] - Cash and cash equivalents as of September 30, 2024, were $7.3 million [3][9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other juri ...

Exhibit 99.1 Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights ● Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025 ...